Overview

Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration

Status:
Completed
Trial end date:
2018-07-12
Target enrollment:
Participant gender:
Summary
Clinical study designed to assess the plasma pharmacokinetic profile and tolerability of Fulvestrant for Injectable Suspension after a single IM dose of Fulvestrant for Injectable Suspension compared to the reference product, Faslodex in healthy female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Eagle Pharmaceuticals, Inc.
Treatments:
Estradiol
Fulvestrant